A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacameten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2018
At a glance
- Drugs Mavacamten (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Adverse reactions
- Acronyms MAVERICK-HCM
- Sponsors MyoKardia
- 02 Apr 2018 According to a MyoKardia media release, Dr. Stephen Heitner, cardiologist at the Oregon Health & Science University Knight Cardiovascular Institute is the principal investigator for this trial.
- 02 Apr 2018 According to a MyoKardia media release, first patient has been dosed, and topline are anticipated in the second half of 2019.
- 02 Apr 2018 Status changed from not yet recruiting to recruiting, according to a MyoKardia media release.